- Home
- AUPH vs VSAT Comparison
AUPH vs VSAT Comparison
Compare AUPH & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- VSAT
- Stock Information
- Founded
- AUPH 1993
- VSAT 1986
- Country
- AUPH Canada
- VSAT United States
- Employees
- AUPH N/A
- VSAT N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- VSAT Radio And Television Broadcasting And Communications Equipment
- Sector
- AUPH Health Care
- VSAT Technology
- Exchange
- AUPH Nasdaq
- VSAT Nasdaq
- Market Cap
- AUPH 999.8M
- VSAT 1.1B
- IPO Year
- AUPH 1999
- VSAT 1996
- Fundamental
- Price
- AUPH $7.85
- VSAT $10.52
- Analyst Decision
- AUPH Strong Buy
- VSAT Buy
- Analyst Count
- AUPH 2
- VSAT 7
- Target Price
- AUPH $11.50
- VSAT $17.14
- AVG Volume (30 Days)
- AUPH 1.1M
- VSAT 2.0M
- Earning Date
- AUPH 05-12-2025
- VSAT 05-23-2025
- Dividend Yield
- AUPH N/A
- VSAT N/A
- EPS Growth
- AUPH N/A
- VSAT N/A
- EPS
- AUPH 0.27
- VSAT N/A
- Revenue
- AUPH $247,295,000.00
- VSAT $4,522,502,000.00
- Revenue This Year
- AUPH $11.86
- VSAT $7.45
- Revenue Next Year
- AUPH $24.96
- VSAT $2.22
- P/E Ratio
- AUPH $29.71
- VSAT N/A
- Revenue Growth
- AUPH 29.20
- VSAT 19.02
- 52 Week Low
- AUPH $4.98
- VSAT $6.69
- 52 Week High
- AUPH $10.67
- VSAT $26.70
- Technical
- Relative Strength Index (RSI)
- AUPH 44.68
- VSAT 65.89
- Support Level
- AUPH $7.89
- VSAT $8.96
- Resistance Level
- AUPH $8.49
- VSAT $10.71
- Average True Range (ATR)
- AUPH 0.30
- VSAT 0.46
- MACD
- AUPH -0.02
- VSAT 0.19
- Stochastic Oscillator
- AUPH 36.95
- VSAT 91.28
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About VSAT ViaSat Inc.
Viasat Inc provides bandwidth technologies and services in three segments: satellite services: which provides satellite-based high-speed broadband services to consumers, enterprises, and commercial airlines; commercial networks: which develops end-to-end communication and connectivity systems; and government systems: which produces network-centric Internet Protocol-based secure government communication systems. A large majority of the firm's revenue is generated in the United States, it also has its presence in non U.S. countries.